South Africa - Timing of Referral to Antiretroviral Clubs Study 2017-2018

Professor Landon Myer

Report generated on: August 4, 2022

Visit our data catalog at: https://www.datafirst.uct.ac.za/dataportal/index.php

Identification

SURVEY ID NUMBER zaf-uct-trac-2017-2018-v1

TITLE

Timing of Referral to Antiretroviral Clubs Study 2017-2018

COUNTRY

Name	Country code
South Africa	zaf

STUDY TYPE

Clinical Trial

ABSTRACT

Data were collected as part of a randomised controlled trial in which adults stable on ART at four months on treatment were randomised to either ongoing clinic care or referral to the local model of differentiated service delivery (community-based adherence clubs). Data collection included face to face interviews, data abstraction of routine care records and phlebotomy for viral load.

KIND OF DATA

Survey and Case Studies

UNIT OF ANALYSIS

Individuals

Version

VERSION DESCRIPTION

v1: Edited, anonymised data for public distribution

VERSION DATE

2022

Scope

NOTES

HIV-related data collected includes the study viral load result (copies/mL), World Health Organization stage prior to the initiation of antiretroviral therapy, Arm to which participant was randomised at enrolment (Club/Clinic; Club=adherence club, Clinic=primary health care clinic), Current antiretroviral therapy regimen, Prior lifelong antiretroviral therapy, and Duration of therapy

Other data collected on individuals includes information on whether they are currently working and/or studying, their household income source and employment type, and receipt of government grants.

Coverage

GEOGRAPHIC UNIT

The data is at the level of health facility

Producers and sponsors

Name	Affiliation
Professor Landon Myer	University of Cape Town

FUNDING AGENCY/SPONSOR

Name	Abbreviation	Role
Medical Research Council	MRC	Funding Agency

Data Collection

DATES OF DATA COLLECTION

Start	End
2017-01	2018-04

DATA COLLECTION MODE

Other

DATA COLLECTION NOTES

Data collection included face-to-face interviews, data abstraction of routine care records, and phlebotomy for viral load.

Questionnaires

OUESTIONNAIRES

Questionnaires, data abstraction, phlebotomy.

Access policy

CONTACTS

Name	Affiliation	Email	URL
DataFirst Support	University of Cape Town	support@data1st.org	www.support.data1st.org

ACCESS CONDITIONS

Public access data for use under a Creative Commons CC-BY (Attribution-only) License

CITATION REQUIREMENTS

Myer, Landon. Timing of Referral to Antiretroviral Clubs Study 2017-2018 [dataset]. Version 1. Cape Town: University of Cape Town. School of Public Health and Family Medicine [producer], 2018. Cape Town: DataFirst [distributor], 2022. DOI: https://doi.org/10.25828/V71J-3B55

ACCESS AUTHORITY

Name	Affiliation	Email	URL
DataFirst	University of Cape Town	support@data1st.org	support.data1st.org

Metadata production

PRODUCERS

Name	Affiliation	Role
DataFirst	University of Cape Town	Metadata producer

DATE OF METADATA PRODUCTION 2022-08-02

DDI DOCUMENT VERSION Version 1

Data Description

Data file	Cases	Variables
trac-2017-2018	650	17

Data file: trac-2017-2018

Cases: 650
Variables: 17

Variables

ID	Name	Label	Question
V18	pid	Patient identifier	
V19	study_visit_no	Study visit number: 1,2, or 3	
V20	vl_result	Study viral load result (copies/mL)	
V21	who_stage	WHO stage prior to the initiation of antiretroviral therapy	
V22	cd4_pre_init	CD4 count taken pre-initiation of antiretroviral therapy	
V23	pre_initiationCD4	Value of CD4 count taken pre-initiation of ART (cells/mm3)	
V24	randomisation_allocation	Model of care to which participant was randomised at enrolment	
V25	work_study	Currently working/studying	
V26	household_income_source	Major source of income for household	
V27	curr_regimen	Current antiretroviral therapy regimen	
V28	prev_art	Prior lifelong antiretroviral therapy	
V29	durart_enrolment	Duration on antiretroviral therapy at enrolment (days)	
V30	durart_v2	Duration on antiretroviral therapy at 2nd study visit (days)	
V31	durart_v3	Duration on antiretroviral therapy at 3rd study visit (days)	
V32	m4window	Attended second study visit within visit window	
V33	m8window	Attended third study visit within visit window	
V34	perprotocol	Included in the per protocol analysis	

Total: 17

PID: Patient identifier

Data file: trac-2017-2018

Overview

Valid: 648 Invalid: 2 Minimum: 9001 Maximum: 9220 Mean: 9109.35 Standard deviation: 63.238

Type: Continuous Decimal: 0 Width: 4 Range: 9001 - 9220 Format: Numeric

STUDY VISIT NO: Study visit number: 1,2, or 3

Data file: trac-2017-2018

Overview

Valid: 648 Invalid: 2

Type: Discrete Decimal: 0 Width: 1 Range: 1 - 3 Format: Numeric

Questions and instructions

CATEGORIES

Value	Category	Cases	
1		220	33.8%
2		216	33.2%
3		212	32.6%
Sysmiss		2	

VL_RESULT: Study viral load result (copies/mL)

Data file: trac-2017-2018

Overview

Valid: 649 Invalid: 0

Type: Discrete Width: 9 Range: - Format: character

Questions and instructions

Value	Category	Cases	
100		2	0.3%
1014		1	0.2%
106		1	0.2%
107		1	0.2%
108845		1	0.2%
109		3	0.5%
115		1	0.2%

119 1 0.2% 1237 1 0.2% 1268 1 0.2% 127 1 0.2% 12838 1 0.2% 139 1 0.2% 1468 1 0.2% 151 1 0.2% 154 1 0.2% 155 1 0.2% 163 1 0.2% 167 1 0.2% 16896 1 0.2% 17394 1 0.2% 17394 1 0.2% 178 1 0.2% 187 1 0.2% 1881 1 0.2% 189 1 0.2% 181 1 0.2% 199 1 0.2% 20 4 0.6% 21 2 0.3% 22 5 0.8% 23 5 0.8% 23 5 0.8% 24 1 0.2%	116221	1	0.2%
1237 1 0.2% 1268 1 0.2% 127 1 0.2% 12838 1 0.2% 139 1 0.2% 151 1 0.2% 154 1 0.2% 155 1 0.2% 167 1 0.2% 16896 1 0.2% 17394 1 0.2% 178 1 0.2% 180 1 0.2% 187 1 0.2% 18813 1 0.2% 199 1 0.2% 199 1 0.2% 20 4 0.6% 2096 1 0.2% 21 2 0.3% 22 5 0.8% 23 5 0.8% 23 5 0.8% 23 5 0.8% 24 1 0.2% 26 2 0.3% 26 2 0.3% <tr< td=""><td>119</td><td>1</td><td>0.2%</td></tr<>	119	1	0.2%
1237 1 0.2% 1268 1 0.2% 127 1 0.2% 12838 1 0.2% 139 1 0.2% 1468 1 0.2% 151 1 0.2% 154 1 0.2% 155 1 0.2% 167 1 0.2% 167 1 0.2% 1689 1 0.2% 17394 1 0.2% 178 1 0.2% 187 1 0.2% 1881 1 0.2% 1881 1 0.2% 199 1 0.2% 20 4 0.6% 2096 1 0.2% 21 2 0.3% 22 5 0.8% 23 5 0.8% 23 5 0.8% 23 5 0.8% 24 1 0.2% 26 2 0.3% <t< td=""><td>120</td><td>1</td><td>0.2%</td></t<>	120	1	0.2%
127 1 0.2% 12838 1 0.2% 139 1 0.2% 1468 1 0.2% 151 1 0.2% 154 1 0.2% 155 1 0.2% 167 1 0.2% 167 1 0.2% 169 1 0.2% 17394 1 0.2% 178 1 0.2% 180 1 0.2% 187 1 0.2% 18813 1 0.2% 199 1 0.2% 20 4 0.6% 20 4 0.6% 21 2 0.3% 23 5 0.8% 23 5 0.8% 23 5 0.8% 23 5 0.8% 23 5 0.8% 23 5 0.8% 23 5 0.8% 23 5 0.8%	1237		0.2%
127 1 0.2% 12838 1 0.2% 139 1 0.2% 1468 1 0.2% 151 1 0.2% 154 1 0.2% 155 1 0.2% 167 1 0.2% 167 1 0.2% 169 1 0.2% 17394 1 0.2% 178 1 0.2% 180 1 0.2% 187 1 0.2% 18813 1 0.2% 199 1 0.2% 20 4 0.6% 20 4 0.6% 21 2 0.3% 23 5 0.8% 23 5 0.8% 23 5 0.8% 23 5 0.8% 23 5 0.8% 23 5 0.8% 23 5 0.8% 23 5 0.8%	1268	1	0.2%
12838 1 0.2% 139 1 0.2% 1468 1 0.2% 151 1 0.2% 154 1 0.2% 155 1 0.2% 163 1 0.2% 167 1 0.2% 16896 1 0.2% 169 1 0.2% 17394 1 0.2% 178 1 0.2% 180 1 0.2% 187 1 0.2% 18813 1 0.2% 199 1 0.2% 20 4 0.6% 2096 1 0.2% 21 2 0.3% 22 5 0.8% 23 5 0.8% 237 1 0.2% 24 1 0.2% 24 1 0.2% 25 5 0.8% 25 5 0.8% 26 2 0.3%			
139 1 0.2% 1468 1 0.2% 151 1 0.2% 154 1 0.2% 155 1 0.2% 163 1 0.2% 167 1 0.2% 16896 1 0.2% 169 1 0.2% 17394 1 0.2% 178 1 0.2% 180 1 0.2% 187 1 0.2% 18813 1 0.2% 199 1 0.2% 20 4 0.6% 2096 1 0.2% 21 2 0.3% 22 5 0.8% 23 5 0.8% 23 5 0.8% 237 1 0.2% 24 1 0.2% 24 1 0.2% 25 5 0.8% 25 5 0.8% 26 2 0.3%			
1468 1 0.2% 151 1 0.2% 154 1 0.2% 155 1 0.2% 163 1 0.2% 167 1 0.2% 16896 1 0.2% 169 1 0.2% 17394 1 0.2% 178 1 0.2% 180 1 0.2% 187 1 0.2% 18813 1 0.2% 199 1 0.2% 20 4 0.6% 20 4 0.6% 20 4 0.6% 20 4 0.6% 20 4 0.6% 20 5 0.3% 21 2 0.3% 22 5 0.8% 23 5 0.8% 23 5 0.8% 23 5 0.8% 23 5 0.8% 24 1 0.2%			
154 1 0.2% 155 1 0.2% 163 1 0.2% 167 1 0.2% 16896 1 0.2% 169 1 0.2% 17394 1 0.2% 178 1 0.2% 180 1 0.2% 187 1 0.2% 18813 1 0.2% 199 1 0.2% 20 4 0.6% 2096 1 0.2% 21 2 0.3% 22 5 0.8% 237 1 0.2% 24 1 0.2% 24 1 0.2% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3%	1468		0.2%
154 1 0.2% 155 1 0.2% 163 1 0.2% 167 1 0.2% 16896 1 0.2% 169 1 0.2% 17394 1 0.2% 178 1 0.2% 180 1 0.2% 187 1 0.2% 18813 1 0.2% 199 1 0.2% 20 4 0.6% 2096 1 0.2% 21 2 0.3% 22 5 0.8% 237 1 0.2% 24 1 0.2% 24 1 0.2% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3%	151	1	0.2%
155 1 0.2% 163 1 0.2% 167 1 0.2% 16896 1 0.2% 169 1 0.2% 17394 1 0.2% 178 1 0.2% 180 1 0.2% 187 1 0.2% 18813 1 0.2% 199 1 0.2% 20 4 0.6% 2096 1 0.2% 21 2 0.3% 22 5 0.8% 23 5 0.8% 23 5 0.8% 237 1 0.2% 24 1 0.2% 25 5 0.8% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3%			
163 1 0.2% 1667 1 0.2% 16896 1 0.2% 169 1 0.2% 17394 1 0.2% 178 1 0.2% 180 1 0.2% 187 1 0.2% 18813 1 0.2% 199 1 0.2% 20 4 0.6% 2096 1 0.2% 21 2 0.3% 22 5 0.8% 23 5 0.8% 237 1 0.2% 24 1 0.2% 24 1 0.2% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3%			
167 1 0.2% 16896 1 0.2% 169 1 0.2% 17394 1 0.2% 178 1 0.2% 180 1 0.2% 187 1 0.2% 18813 1 0.2% 199 1 0.2% 20 4 0.6% 2096 1 0.2% 21 2 0.3% 22 5 0.8% 23 5 0.8% 237 1 0.2% 24 1 0.2% 24 1 0.2% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3% <			
1699 1 0.2% 17394 1 0.2% 174 1 0.2% 1878 1 0.2% 1880 1 0.2% 1887 1 0.2% 18813 1 0.2% 199 1 0.2% 20 4 0.6% 2096 1 0.2% 21 2 0.3% 22 5 0.8% 23 5 0.8% 237 1 0.2% 24 1 0.2% 24 1 0.2% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3% 26 2 0.3%			
169 1 0.2% 17394 1 0.2% 174 1 0.2% 178 1 0.2% 180 1 0.2% 187 1 0.2% 18813 1 0.2% 199 1 0.2% 20 4 0.6% 2096 1 0.2% 21 2 0.3% 22 5 0.8% 23 5 0.8% 237 1 0.2% 24 1 0.2% 24 1 0.2% 25 5 0.8% 2545 1 0.2% 266 2 0.3% 261 1 0.2% 268 1 0.2% 27 1 0.2%			
17394 1 0.2% 174 1 0.2% 178 1 0.2% 180 1 0.2% 187 1 0.2% 18813 1 0.2% 199 1 0.2% 20 4 0.6% 2096 1 0.2% 21 2 0.3% 22 5 0.8% 23 5 0.8% 237 1 0.2% 24 1 0.2% 24 1 0.2% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 261 1 0.2% 268 1 0.2% 27 1 0.2%	169		
174 1 0.2% 178 1 0.2% 180 1 0.2% 187 1 0.2% 18813 1 0.2% 199 1 0.2% 20 4 0.6% 2096 1 0.2% 21 2 0.3% 22 5 0.8% 23 5 0.8% 237 1 0.2% 24 1 0.2% 24 1 0.2% 25 5 0.8% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 261 1 0.2% 27 1 0.2%			
178 1 0.2% 180 1 0.2% 187 1 0.2% 18813 1 0.2% 199 1 0.2% 20 4 0.6% 2096 1 0.2% 21 2 0.3% 22 5 0.8% 23 5 0.8% 237 1 0.2% 24 1 0.2% 24 1 0.2% 25 5 0.8% 25 5 0.8% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 261 1 0.2% 27 1 0.2%			
180 1 0.2% 187 1 0.2% 18813 1 0.2% 191 1 0.2% 199 1 0.2% 20 4 0.6% 2096 1 0.2% 21 2 0.3% 22 5 0.8% 23 5 0.8% 237 1 0.2% 24 1 0.2% 25 5 0.8% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 261 1 0.2% 268 1 0.2% 27 1 0.2%			
187 1 0.2% 18813 1 0.2% 191 1 0.2% 199 1 0.2% 20 4 0.6% 2096 1 0.2% 21 2 0.3% 22 5 0.8% 23 5 0.8% 237 1 0.2% 2386 1 0.2% 24 1 0.2% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 261 1 0.2% 268 1 0.2% 27 1 0.2%			
18813 1 0.2% 199 1 0.2% 20 4 0.6% 2096 1 0.2% 21 2 0.3% 22 5 0.8% 23 5 0.8% 237 1 0.2% 2386 1 0.2% 24 1 0.2% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 261 1 0.2% 268 1 0.2% 27 1 0.2%			
191 1 0.2% 199 1 0.2% 20 4 0.6% 2096 1 0.2% 21 2 0.3% 22 5 0.8% 23 5 0.8% 237 1 0.2% 24 1 0.2% 24 1 0.2% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 261 1 0.2% 268 1 0.2% 27 1 0.2%	18813		0.2%
199 1 0.2% 20 4 0.6% 2096 1 0.2% 21 2 0.3% 22 5 0.8% 23 5 0.8% 237 1 0.2% 2386 1 0.2% 24 1 0.2% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 261 1 0.2% 268 1 0.2% 27 1 0.2%			
20 4 0.6% 2096 1 0.2% 21 2 0.3% 22 5 0.8% 23 5 0.8% 237 1 0.2% 2386 1 0.2% 24 1 0.2% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 261 1 0.2% 268 1 0.2% 27 1 0.2%			0.2%
21 2 0.3% 22 5 0.8% 23 5 0.8% 237 1 0.2% 2386 1 0.2% 24 1 0.2% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 261 1 0.2% 268 1 0.2% 27 1 0.2%	20		
21 2 0.3% 22 5 0.8% 23 5 0.8% 237 1 0.2% 2386 1 0.2% 24 1 0.2% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 261 1 0.2% 268 1 0.2% 27 1 0.2%	2096	1	0.2%
23 5 0.8% 237 1 0.2% 2386 1 0.2% 24 1 0.2% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 261 1 0.2% 268 1 0.2% 27 1 0.2%	21	2	0.3%
237 1 0.2% 2386 1 0.2% 24 1 0.2% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 261 1 0.2% 268 1 0.2% 27 1 0.2%	22	5	0.8%
2386 1 0.2% 24 1 0.2% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 261 1 0.2% 268 1 0.2% 27 1 0.2%	23	5	0.8%
24 1 0.2% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 261 1 0.2% 268 1 0.2% 27 1 0.2%	237	1	0.2%
24 1 0.2% 25 5 0.8% 2545 1 0.2% 26 2 0.3% 261 1 0.2% 268 1 0.2% 27 1 0.2%	2386	1	0.2%
2545 1 0.2% 26 2 0.3% 261 1 0.2% 268 1 0.2% 27 1 0.2%	24		0.2%
26 2 0.3% 261 1 0.2% 268 1 0.2% 27 1 0.2%	25	5	0.8%
26 2 0.3% 261 1 0.2% 268 1 0.2% 27 1 0.2%			0.2%
261 1 0.2% 268 1 0.2% 27 1 0.2%	26	2	0.3%
268 1 0.2% 27 1 0.2%	261	1	
	268	1	0.2%
28 5 0.8%	27	1	0.2%
	28	5	0.8%

29	4	0.6%
30	1	0.2%
307	1	0.2%
307654	1	0.2%
31	1	0.2%
32	1	0.2%
33	3	0.5%
331	1	0.2%
34	2	0.3%
341028	1	0.2%
3433	1	0.2%
35	1	0.2%
36	2	0.3%
37	1	0.2%
38	2	0.3%
38161	1	0.2%
39	1	0.2%
391	1	0.2%
40	3	0.5%
406012	1	0.2%
41	3	0.5%
42	1	0.2%
43	2	0.3%
432	1	0.2%
45	1	0.2%
47	3	0.5%
476	1	0.2%
4799	1	0.2%
48	3	0.5%
49053	1	0.2%
50	1	0.2%
50333	1	0.2%
51	2	0.3%
5263	1	0.2%
53	1	0.2%
54	2	0.3%
56	2	0.3%
561	1	0.2%
5635	1	0.2%

5665	1	0.2%
577	1	0.2%
59	1	0.2%
60	1	0.2%
61	2	0.3%
624	1	0.2%
64	2	0.3%
6459	1	0.2%
68	1	0.2%
69	1	0.2%
70	1	0.2%
719	1	0.2%
73	1	0.2%
77	1	0.2%
7766	1	0.2%
78	1	0.2%
80	2	0.3%
81	1	0.2%
86	1	0.2%
86831	1	0.2%
94	1	0.2%
97	1	0.2%
98	1	0.2%
<100	7	1.1%
<20	167	25.7%
LDL	319	49.2%
copies/mL	1	0.2%

WHO_STAGE: WHO stage prior to the initiation of antiretroviral therapy

Data file: trac-2017-2018

Overview

Valid: 639 Invalid: 11

Type: Discrete Decimal: 0 Width: 1 Range: 1 - 5 Format: Numeric

Questions and instructions

Value	Category	Cases	
-------	----------	-------	--

1	1	389	59.8%
2	2	133	20.5%
3	3	86	13.2%
4	4	19	2.9%
5	unknown	12	1.8%
Sysmiss		11	

CD4_PRE_INIT: CD4 count taken pre-initiation of antiretroviral therapy

Data file: trac-2017-2018

Overview

Valid: 642 Invalid: 8

Type: Discrete Decimal: 0 Width: 1 Range: 1 - 2 Format: Numeric

Questions and instructions

CATEGORIES

Value	Category	Cases	
1	No	9	1.4%
2	Yes	633	97.4%
Sysmiss		8	

PRE_INITIATIONCD4: Value of CD4 count taken pre-initiation of ART (cells/mm3)

Data file: trac-2017-2018

Overview

Valid: 633 Invalid: 17 Minimum: 5 Maximum: 1347 Mean: 395.316 Standard deviation: 234.488

Type: Continuous Decimal: 0 Width: 4 Range: 5 - 1347 Format: Numeric

RANDOMISATION_ALLOCATION: Model of care to which participant was randomised at enrolment

Data file: trac-2017-2018

Overview

Valid: 648 Invalid: 2

Type: Discrete Decimal: 0 Width: 1 Range: 1 - 2 Format: Numeric

Questions and instructions

Value	Category	Casas	
Value	Category	Cases	
	, ,		

1	Clinic	318	48.9%
2	Club	330	50.8%
Sysmiss		2	

WORK_STUDY: Currently working/studying

Data file: trac-2017-2018

Overview

Valid: 648 Invalid: 2

Type: Discrete Decimal: 0 Width: 1 Range: 1 - 2 Format: Numeric

Questions and instructions

CATEGORIES

Value	Category	Cases	
1	No	228	35.1%
2	Yes	420	64.6%
Sysmiss		2	

HOUSEHOLD_INCOME_SOURCE: Major source of income for household

Data file: trac-2017-2018

Overview

Valid: 648 Invalid: 2

Type: Discrete Decimal: 0 Width: 1 Range: 1 - 9 Format: Numeric

Questions and instructions

Value	Category	Cases	
1	Disability grant	15	2.3%
2	Full-time employment	384	59.1%
3	Informal employment	74	11.4%
4	None	9	1.4%
5	Other	23	3.5%
6	Other grant	6	0.9%
7	Part-time employment	84	12.9%
8	Pension	12	1.8%
9	Social grant	41	6.3%
Sysmiss		2	

CURR_REGIMEN: Current antiretroviral therapy regimen

Data file: trac-2017-2018

Overview

Valid: 648 Invalid: 2

Type: Discrete Decimal: 0 Width: 1 Range: 1 - 1 Format: Numeric

Questions and instructions

CATEGORIES

Value	Category	Cases	
1	Tenofovir + Emtricitabine + Efavirenz	648	99.7%
Sysmiss		2	

PREV_ART: Prior lifelong antiretroviral therapy

Data file: trac-2017-2018

Overview

Valid: 648 Invalid: 2

Type: Discrete Decimal: 0 Width: 1 Range: 1 - 2 Format: Numeric

Questions and instructions

CATEGORIES

Value	Category	Cases	
1	No	495	76.2%
2	Yes	153	23.5%
Sysmiss		2	

DURART_ENROLMENT: Duration on antiretroviral therapy at enrolment (days)

Data file: trac-2017-2018

Overview

Valid: 648 Invalid: 2 Minimum: -98 Maximum: 154 Mean: 128.377 Standard deviation: 19.914

Type: Continuous Decimal: 0 Width: 3 Range: -98 - 154 Format: Numeric

DURART_V2: Duration on antiretroviral therapy at 2nd study visit (days)

Data file: trac-2017-2018

Overview

Valid: 644 Invalid: 6 Minimum: 202 Maximum: 369 Mean: 255.615 Standard deviation: 25.834

Type: Continuous Decimal: 0 Width: 3 Range: 202 - 369 Format: Numeric

DURART V3: Duration on antiretroviral therapy at 3rd study visit (days)

Data file: trac-2017-2018

Overview

Valid: 636 Invalid: 14 Minimum: 315 Maximum: 452 Mean: 368.623 Standard deviation: 22.257

Type: Continuous Decimal: 0 Width: 3 Range: 315 - 452 Format: Numeric

M4WINDOW: Attended second study visit within visit window

Data file: trac-2017-2018

Overview

Valid: 650 Invalid: 0

Type: Discrete Decimal: 0 Width: 1 Range: 0 - 1 Format: Numeric

Questions and instructions

CATEGORIES

Value	Category	Cases	
0		27	4.2%
1		623	95.8%

M8WINDOW: Attended third study visit within visit window

Data file: trac-2017-2018

Overview

Valid: 650 Invalid: 0

Type: Discrete Decimal: 0 Width: 1 Range: 0 - 1 Format: Numeric

Questions and instructions

Value	Category	Cases	
0		35	5.4%
1		615	94.6%

PERPROTOCOL: Included in the per protocol analysis

Data file: trac-2017-2018

Overview

Valid: 648 Invalid: 2

Type: Discrete Decimal: 0 Width: 1 Range: 0 - 1 Format: Numeric

Questions and instructions

Value	Category	Cases	
0		60	9.2%
1		588	90.5%
Sysmiss		2	

Download related resources

Other materials

Timing of Referral to Adherence Clubs (TRAC)

Title Timing of Referral to Adherence Clubs (TRAC)

Author(s) Landon Myer
Date 2022-01-01
Country South Africa
Language English

Contributor(s) This is the protocol document for the study

Filename trac-2017-2018-protocol-v3.pdf